-+ 0.00%
-+ 0.00%
-+ 0.00%

Jones Trading Upgrades Spyre Therapeutics to Buy, Announces $64 Price Target

Benzinga·12/01/2025 13:17:49
Listen to the news
Jones Trading analyst Debanjana Chatterjee upgrades Spyre Therapeutics (NASDAQ:SYRE) from Hold to Buy and announces $64 price target.